A Study Investigating the Safety and Tolerability of an Immune Treatment in Cancer Patients With Lesions to the Skin
Status:
Recruiting
Trial end date:
2025-07-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and tolerability of 2141-V11 in people who
have cancer that does not respond to standard treatment and who have skin lesions (skin
tumors) associated with their cancer. The study will also test how the body processes and
responds to 2141-V11, and if the study drug has cancer fighting activity in people. The study
drug activates a naturally occurring protein called CD40. By activating CD40, cells of the
immune system are better able to identify and kill cancer cells.
We are testing if injection of 2141-V11 into metastasis to the skin will be safe and well
tolerated, and may result in immune activation in patients with solid tumors that have
metastasis to the skin.